trial · primary record
Darolutamide (Nubeqa, BAY1841788)
Cancer
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 774 |
| Primary completion | 2028-06-26 |
| Primary endpoint | Incidence of treatment-emergent adverse events (TEAEs) |
| Registry ID | NCT04464226 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:38:59.271Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04464226
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- DAROLUTAMIDE · approval
- Darolutamide · compound